Trial site
National Specialised Hospital For Active Treatment Of Haematological Diseases
Sofia, 1756, BulgariaEU-13 widening countryNot linked to an institution yet
- 6running trials
- 1closed trial
The trials here
What the 7 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 1/21 trial
- Status
- Active, not recruiting5 trials
- Completed1 trial
- Recruiting1 trial
- Lead sponsor
- Agios Pharmaceuticals, Inc.2 trials
- AbbVie Deutschland GmbH & Co. KG1 trial
- argenx1 trial
- Bayer1 trial
- Genmab1 trial
- and 1 more
Running trials
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499· Phase 3· argenx· Source
Active, not recruiting
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2024-510965-41-00· Phase 3· AbbVie Deutschland GmbH & Co. KG· Source
Active, not recruiting
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976· Phase 3· Genmab· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
NCT04770753· Phase 3· Agios Pharmaceuticals, Inc.· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
NCT04770779· Phase 3· Agios Pharmaceuticals, Inc.· Source
Active, not recruiting
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734· Phase 3· Swedish Orphan Biovitrum· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error